sulfonylurea vs glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Drugs for Diabetes Mellitus

Obes Rev 25(11):e13811 Astrup A et al (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

Challenges: Responding to a Market That Wont Wait The rapid rise of GLP-1s has introduced significant operational and strategic challenges across the pharmaceutical manufacturing landscape

Some research suggests that taking 30 minutes versus five minutes to eat leads to greater secretion of GLP-1

Around 40% of Americans ages 20 and older are considered obese, and nearly 10% are severely obese

Probably not, once you account for what you're actually getting

GLP-1 agonist oral formulations are significantly less expensive than injectable forms